SCHEMBL10280286

SCHEMBL10280286

C(=N/Nc1nc2ccccc2[nH]1)\c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 18/20 1.00
▸ GAA P10253 17/20 1.00
▸ NPC1 O15118 14/20 1.00
▸ RAB9A P51151 14/20 1.00
▸ MEN1 O00255 10/20 1.00
▸ KMT2A Q03164 10/20 1.00
▸ SMN1; SMN2 Q16637 6/20 1.00
▸ TDP1 Q9NUW8 5/20 0.70
▸ LMNA P02545 4/20 0.70
▸ L3MBTL1 Q9Y468 2/20 0.70
▸ HTT P42858 5/20 0.69
▸ ALDH1A1 P00352 5/20 0.68
▸ HPGD P15428 4/20 0.68
▸ KDM4E B2RXH2 4/20 0.68
▸ NPSR1 Q6W5P4 4/20 0.68
▸ GLA P06280 1/20 0.68
▸ TP53 P04637 3/20 0.67
▸ PKM P14618 2/20 0.66
▸ NFKB1 P19838 1/20 0.65
▸ NFKB2 Q00653 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL880223 0.90 GAA (1.00) MAPTGAANPC1RAB9AMEN1
SCHEMBL23906527 0.88 MAPT (0.79) MAPTGAANPC1RAB9AMEN1
SCHEMBL880195 0.86 GAA (0.75) MAPTGAANPC1RAB9AMEN1
SCHEMBL10280285 0.85 MAPT (0.73) MAPTGAANPC1RAB9AMEN1
SCHEMBL880461 0.85 MAPT (0.76) MAPTGAANPC1RAB9AMEN1
SCHEMBL10280287 0.84 MAPT (0.76) MAPTGAANPC1RAB9AMEN1
SCHEMBL15359675 0.84 MAPT (0.76) MAPTGAANPC1RAB9AMEN1
SCHEMBL14942678 0.82 MAPT (0.68) MAPTGAANPC1RAB9AMEN1
SCHEMBL880212 0.82 PLA2G10 (0.72) MAPTGAANPC1RAB9AMEN1
SCHEMBL880217 0.80 FAAH (0.66) MAPTGAANPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440705-B2 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2013-05-14 — — US disclosed
US-8440705-B2 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2013-05-14 — — US disclosed
EP-2433634-A2 Compounds, compositions and methods of inhibiting a-synuclein toxicity The Whitehead Institute for Biomedical Research (US) 2012-03-28 — — EP disclosed
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2008-10-23 — — US disclosed
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity SNCA, PARK7, HTT MAPT 30/4885GAA 62/4885NPC1 2064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback